ResMed Says PTAB Judges, In Rulings Issued From December 4 To December 7, 2023, Found That All The Challenged Claims Across Seven Patents Were Invalid
Portfolio Pulse from Benzinga Newsdesk
ResMed has received unfavorable rulings from the PTAB, with judges declaring all challenged claims across seven patents invalid. These patents were the subject of a June 2021 patent infringement lawsuit filed by NYU against ResMed, alleging that ResMed's AirSense 10 AutoSet flow generators infringed on NYU's patents.
December 11, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ResMed's patents have been invalidated by PTAB, which could negatively impact the company's ongoing litigation with NYU and potentially affect its product offerings.
The invalidation of patents by PTAB is a significant legal blow to ResMed, as it undermines the company's defense against NYU's infringement claims. This could lead to potential financial liabilities or injunctions against selling the implicated products, which would likely have a negative impact on ResMed's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100